Will Novartis’ Pasireotide Find A Simpler Road To Approval In Cushing’s?
This article was originally published in Pharmaceutical Approvals Monthly
With a mechanism of action more suited to the traditional endpoints in Cushing’s, and a randomized trial, the pasireotide review could be more straightforward than Korlym’s.
You may also be interested in...
The latest oncology development news and highlights from our US FDA Performance Tracker.
Rigorous planning and a multidisciplinary team including database experts and healthcare specialists with local knowledge are vital to effective real-world evidence, white paper shows.
The latest submission and expedited review program news and highlights from our US FDA Performance Tracker.